A Dual 5-HT2A and 5-HT2C Receptor Inverse Agonist Developed to Address the Limitations of Pimavanserin
Genentech's fenebrutinib, a non-covalent BTK inhibitor in Ph. III, showed significant CNS exposure and reduced new brain lesions in Ph. II for relapsing MS. It is the only reversible BTK inhibitor in Ph. III for MS, potentially differentiating on safety from covalent inhibitors.
Reference News
A Dual 5-HT2A and 5-HT2C Receptor Inverse Agonist Developed to Address the Limitations of Pimavanserin
Genentech's fenebrutinib, a non-covalent BTK inhibitor in Ph. III, showed significant CNS exposure and reduced new brain lesions in Ph. II for relapsing MS. It is the only reversible BTK inhibitor in Ph. III for MS, potentially differentiating on safety from covalent inhibitors.